Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E6KN
|
||||
| Former ID |
DNCL003589
|
||||
| Drug Name |
GSK2647544
|
||||
| Synonyms |
GSK-2647544
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 1 | [1] | ||
| Company |
GlaxoSmithKline
|
||||
| Target and Pathway | |||||
| Target(s) | Lipoprotein-associated phospholipase A2 | Target Info | Modulator | [2] | |
| KEGG Pathway | Ether lipid metabolism | ||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Pathway Interaction Database | Lissencephaly gene (LIS1) in neuronal migration and development | ||||
| WikiPathways | IL1 and megakaryotyces in obesity | ||||
| Synthesis, Secretion, and Deacylation of Ghrelin | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01924858) A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1432). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.